Replies to post #159915 on Biotech Values

[DewDiligence]

Why does a large firm like Roche need to partner here with a small firm like Ascletis? Doesn't that alone speak to Roche's confidence, or lack thereof, of the opportunity for danoprevir in China?

Roche’s attempt to develop Danoprevir (or any other drug) as a constituent of an all-oral combination has been an abysmal failure, so it makes sense for Roche to salvage whatever they can from Danoprevir in geographies where interferon will remain part of the SoC for several more years.